Helena Tayton-Martin
Founder at ADAPTIMMUNE THERAPEUTICS PLC
Net worth: 474 102 $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Mott | M | 58 |
Adaptimmune Ltd.
 Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | 10 years |
| Adrian Rawcliffe | M | 52 | 9 years | |
| Margaret Henry | F | - |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | - |
| Ali Behbahani | M | 47 |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | 10 years |
| Gavin Wood | M | 54 |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | 4 years |
| Elliot Norry | M | 61 | 9 years | |
| Joanna Brewer | M | 47 | 15 years | |
| John Furey | M | 59 | 6 years | |
| Lawrence Alleva | M | 74 | 9 years | |
| Andrew Muratore | M | - | 3 years | |
| Deborah Baron | F | 55 | 3 years | |
| William Bertrand | M | 59 | 7 years | |
| John Lunger | M | 55 | 7 years | |
| Sharp Kerry | F | - | 9 years | |
| Phil Bassett | M | - | - | |
| Kathleen Large | F | 64 | 5 years | |
| Juli P. Miller | M | - | 8 years | |
| Priti Hegde | M | 52 | 1 years | |
| Adrian George Rawcliffe | M | - |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | - |
| Kristen Hege | M | 60 | 1 years | |
| Garry Menzel | M | 59 | 1 years | |
| Andrew Allen | M | 57 | 1 years | |
| Dana Lynch | F | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| James Noble | M | 65 |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom.
Avidex Ltd.
 Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | 23 years |
| Niclas Stiernholm | M | - | 8 years | |
| James Parsons | M | 58 | 10 years | |
| Robert A. Uger | M | 53 | 8 years | |
| Ian Michael Laing | M | 78 |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | 1 years |
| Peter Thompson | M | 64 |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | 4 years |
| Bent K. Jakobsen | M | - |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | - |
| J. Kenneth Charles Knowles | M | 77 |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | 1 years |
| Calvin Stiller | M | 83 | 8 years | |
| Robert L. Kirkman | M | 75 | 8 years | |
| Barbara Duncan | F | 59 |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | 7 years |
| Jan Skvarka | M | 57 | 2 years | |
| Charles Sigal | M | 72 |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | 8 years |
| Penka Petrova | M | 56 | 8 years | |
| John Bell | M | 71 |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | - |
| Russell Smith | M | - |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | 10 years |
| Luke Beshar | M | 65 | 7 years | |
| Sãbastien Desprez | M | - | 5 years | |
| Neill Moray MacKenzie | M | - |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | 6 years |
| Gwendolyn Binder-Scholl | M | 49 | 8 years | |
| Scott Myers | M | 57 | - | |
| Rosemary Harrison | M | 41 | 1 years | |
| Giles Kerr | M | 65 | 4 years | |
| Michael G. Moore | M | - | 7 years | |
| Michael Kamarck | M | 73 | 1 years | |
| Paolo Pucci | M | 63 | 1 years | |
| Thomas Reynolds | M | 65 | 7 years | |
| Tal Zaks | M | 58 | 7 years | |
| Paul Walker | M | 49 | 1 years | |
| Wenyong Wang | M | - | - | |
| Paul Stead | M | - | - | |
| Jerry Christopher Benjamin | M | 83 |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | - |
| Ingmar Bruns | M | 49 | 1 years | |
| Brian Jahns | M | - | - | |
| Yaping Shou | M | - | 2 years | |
| Joe Apostolico | M | - | 2 years | |
| Joseph Apostolico | M | - | - | |
| Lini Pandite | M | 65 | 2 years | |
| Benjamin Looker | M | 42 | - | |
| Cintia Piccina | M | 51 | 1 years | |
| Michael Blackton | M | - | - | |
| Ian Kimber | M | - |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | - |
| Trupti Trivedi | F | - | - | |
| Abdelmalik Slassi | M | 62 | 3 years | |
| Rafael Amado | M | 60 | 4 years | |
| William C. Roberts | M | 54 | - | |
| Eric Sievers | M | 60 | 3 years | |
| David McGibney | M | - |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | - |
| Catherine Mackey | M | 68 | - | |
| Nick Cross | M | - |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | - |
| Nicholas Cross | M | - |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | 8 years |
| Peter Doyle | M | - |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | - |
| James M. T. Cochrane | M | 80 |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | - |
| Iain Charles Wilcock | M | 63 |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | - |
| Frank Armstrong | M | 67 |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | 7 years |
| Michael R. Garone | M | 66 | 1 years | |
| Anne-Marie Martin | M | 52 | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 55 | 68.75% |
| Canada | 25 | 31.25% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Helena Tayton-Martin
- Personal Network
